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Abstract 
Background and purpose: Many HIV-infected children in Bali have started antiretroviral therapy (ART), but loss to 
follow up (LTFU) is a continuing concern, and the issue of childhood adherence is more complex compared to adults. 
Methods: This was a retrospective study among cohort of 138 HIV+ children on ART in Sanglah General Hospital, 
Denpasar, Bali from January 2010 to December 2015. Kaplan-Meier analysis was used to describe incidence and median 
time to LTFU/mortality and Cox Proportional Hazard Model was used to identify predictors. Variables which were 
analysed were socio-demographic characteristics, birth history, care giver and clinical condition of the children.  
Results: Mean age when starting ARV therapy was 3.21 years. About 25% experienced LTFU/death by 9.1 month 
resulting in an incidence rate of 3.28 per 100 child month. The higher the WHO stage, the higher the risk for 
LTFU/mortality along with low body weight (AHR=0.90; 95%CI: 0.82-0.99).  
Conclusion:  Clinical characteristics were found as predictors for LTFU/mortality among children on ART. 
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Abstrak  
Latar belakang dan tujuan: Anak yang terinfeksi HIV dan sudah memperoleh terapi antiretroviral (ART) di Bali, 
jumlahnya cukup banyak, akan tetapi lost to follow up (LTFU) masih cukup substansial. LTFU dan kematian pada anak 
yang sedang dalam ART berbeda dan lebih kompleks dibandingkan dengan orang dewasa.  
Metode: Desain penelitian adalah retrospektif pada kohor sebanyak 138 anak HIV positif yang menerima ART di 
Rumah Sakit Umum Pusat Sanglah, Denpasar Bali antara Januari 2010 sampai Desember 2015. Analisis Kaplan-Meier 
digunakan untuk menggambarkan tingkat kejadian dan waktu median untuk kematian. Cox Proportional Hazard Model 
digunakan untuk mengidentifikasi prediktornya. Variabel yang dianalisa adalah karakteristik sosio-demografis pasien, 
riwayat persalinan, pengasuh dan karakteristik klinis.  
Hasil: Mean usia ketika anak mulai terapi ARV adalah 3,21 tahun. Sebanyak 25% mengalami LTFU atau kematian 
dalam waktu 9,1 bulan sehingga tingkat kejadian 3,28 per 100 anak-bulan. Anak dengan Stadium WHO yang lebih tinggi 
saat memulai ART, mempunyai risiko untuk LTFU dan atau kematian.  Variabel yang dijumpai sebagai prediktor LTFU 
dan kematian adalah berat badan rendah ketika  anak datang pertama kali ke rumah sakit  (AHR=0,90; 95%CI: 0,82-
0,99), sedangkan karakteristik sosio-demografis, riwayat persalinan, dan pengasuh tidak dijumpai sebagai prediktor. 
Simpulan: Karakteristik klinis dijumpai sebagai prediktor LFTU atau kematian pada anak dengan ART. 
Kata kunci: Loss to follow up, kematian, anak, ARV, Indonesia 
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Background 
The UNAIDS estimated that in 2013 there were 
25,000 (16,000 - 37,000) children aged  0-14 
months living with HIV in Indonesia.1  
Paediatric ART coverage globally is still 
lagging behind with 1 in 4 children receiving 
these life-prolonging medications, compared 
to 1 in 3 adults.2  
Since drug treatment has no definite 
timeframe, people living with HIV will most 
likely take the medication for the rest of 
their lives, possibly contributing  to lost to 
follow up (LTFU).3 Nevertheless there is a 
paucity of data on the rates of LTFU from 
HIV care and concerning the factors 
associated with LTFU especially in resource-
limited settings.4 Additionally the situation 
of LTFU in children is vastly different and 
more complex when compared to adults: 
children are dependent on their caregivers, 
and the child’s outcome may be linked to 
predicament of the caregiver.5 
A high mortality rate, especially in 
the first 3 months of ART initiation, is owing 
to the fact that many children start 
treatment at an advanced stage of illness, 
particularly in resource-poor settings. Such 
death might be misclassified as early LTFU if 
not appropriately reported.6 
Sanglah General Hospital in 
Denpasar is the central referral hospital for 
the Province of Bali Indonesia, as well as for 
other provinces that lie to the east of Bali 
such as West and East Nusa Tenggara. In 
addition, Sanglah General Hospital is the 
largest service provider in the province of 
Bali capacitated in providing ARV therapy to 
children. The majority of children were 
referred to the hospital from outside clinics 
or hospitals and only very few came from 
the prevention mother to child transmission 
(PMTCT) program.  
This study was the first to explore the 
predictors of LTFU and mortality in HIV+ 
children in Bali. 
 
Method 
A retrospective longitudinal survival analysis 
was performed in Sanglah General Hospital 
in Denpasar. The medical records of children 
enrolled in the ARV therapy program from 
1st of January 2010 till 31st of December 
2015 of the paediatric department, were 
incorporated, resulting in a total of 211 
medical records. Records were examined 
especially regarding patients who were 
continually taking ARV for 12 months or 
longer or who were LTFU/died prior the 12 
month-mark. Any patients that were 
transferred within the first year of ART or 
enrolled <4 month before database closure 
were excluded. The hospital defines 
“children” up to the age of 12 years old.  
LTFU was defined as not returning to 
the hospital for 90 days or longer after the 
last appointment during the first year of 
ART. If the patient returns after 90 days of 
LTFU and re-accesses therapy only the first 
LTFU will be counted and further initiation 
will be excluded. However, if a child is LTFU 
due to death is difficult to determine if the 
child did not die in the hospital. Therefore 
LTFU and mortality were grouped as one in 
this study and not analysed separately.  
In this study the predictors for LTFU 
were grouped into three groups: children’s 
demographic characteristics, socioeconomic 
background and children’s clinical condition, 
including: gender, address, age at first visit, 
age at ARV initiation, ARV starting year, 
primary care giver (PCG) characteristics, 
WHO stage at first visit and at starting ART,7 
weight (kg) at first visit, hemoglobin state, 
CD4%, CD4 cell count total, presence of 
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malnutrition, TB, and anaemia. All data were 
reviewed as recorded in the medical record. 
The collected data were analysed by 
STATA version 12. Survival analysis was 
carried out as analysis of median time to 
LTFU/mortality. Kaplan-Meier analysis was 
used to demonstrate survival analysis per 
month. Cox proportional hazards model was 
used to analysed the significance of the 
independent variables towards 
LTFU/mortality. The Cox regression model 
using the stepwise method was based on the 
bivariate analysis with a p-value < 0.10.  
Ethical clearance approval 
was obtained from the Ethical Committee 
from School of Medicine Universitas 
Udayana/Sanglah General Hospital. Data 
were anonymized and handled confidentially 
during all phases of research activities.  
 
Result 
total subjects analysed were 138, as 41 were 
excluded and 32 medical records could not 
be found. Of the total subjects, 37 were 
LTFU and 6 died within the first year of ARV 
therapy.   
The overall median age during the 
first visit was 2.6 years old and when starting 
ART was 3.21 years old. In the 
LTFU/mortality group, the children were 
much younger compared to the group that 
continued. With each year of age, at the first 
visit, there is a 17% (HR=0.83) higher chance 
in continuing therapy. In both groups ART 
was initiated about 6 months after the first 
visit. Variables such as gender, address, 
starting year or PCG did not show any 
significance. 
The result of Kaplan-Meier analysis 
related to median time of LTFU/death is 
shown in Figure 1. Of all patients receiving 
ART, 25% experienced LTFU/death by 9.1 
months resulting in an incidence rate of 
3.28/100 child-month. The median time of 
50% of LTFU and mortality within 12 months 
of ARV therapy, was not calculated in this 
study.  
The most common main complaint 
during the first visit was diarrhea (20.29%), 
followed by shortness of breath (15.94%) 
and   fever   (14.49%).   Less   than 10% 
directly consulted to VCT without any 
underlying health problem.  
In general, children who 
experienced LTFU/death arrived at the 
hospital at a higher WHO stage.  However, 
only the WHO staging at the time of ART 
initiation was significant (p=0.01). Table 1 
also shows the higher the WHO stage the 
higher the chance of LTFU/mortality. 
 The children, who continued 
therapy >1 year had a 2.5 kg higher median 
weight compared to the children that were 
LTFU/death. With each increase of one 
kilogram, there is a protective factor of 12% 
(AHR=0.88; 95%CI: 0.803-0.966).  
Malnutrition was the most common 
opportunistic infection (OI) over all. The 
highest risk for LTFU/death was in children 
with anaemia, with a risk of 4.62 (AHR=4.62; 
95%CI: 2.42-8.82). A child with malnutrition 
had a 2.57 higher (AHR=2.57; 95%CI: 1.41-
4.67) chance of LTFU/death compared to a 
child with normal/good nutrition (Table 1).  
Variables entered in the step-wise 
regression model, were: age at first visit 
(years), age at ARV initiation (years), WHO 
stage when starting ART, weight at first visit, 
and CD4%. The results are shown in Table 2. 
 Even though CD4% as well as WHO 
staging are not significant in this model, they 
are still included due to their 
pathophysiological reasons. It is important 
to note that WHO staging and weight do not 
correlate in this study.  
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Figure: 1 Kaplan-Meier Survival Estimate
Discussion 
This study was the first to explore LTFU and 
mortality in children receiving ARV therapy 
in Bali.  
A total of 69.84% (95 cases) 
continued to take ARV therapy for more 
than 12 months, and 31.16% (43 cases) 
discontinued therapy, within the first year of 
initiation. The overall incidence rate of LTFU 
and mortality combined was 3.28 per 100 
child-month. Comparing it to other studies is 
problematic since most studies do not 
combine LTFU and mortality. In HIV infected 
children in Asia LTFU and death rates were 
4.2 (3.7-4.8) and 2.1 (1.7-2.5) per 100 
person-years, respectively.8  
A total of 65.94% of children started 
ART at stage III/IV.  The higher the WHO 
stage when starting the ARV therapy, the 
higher the risk for LTFU/mortality (Table 1).  
Hence, it can be assumed that the majority, 
which are LTFU might have died, and 
therefore did not return to the hospital. 
Some children presented when already very 
unwell, and their general health status 
needed to be addressed before ARV therapy 
could be given. The overall high number of 
malnutrition provides insight into why the 
overall body weight during the first visit is 
lower in the LTFU/mortality group. Body 
weight at first visit is about 2.5 kg lighter in 
the LFTU/mortality group. Therefore, the 
weight level at the beginning has a 
protective factor of 10% (adjusted HR= 
0.903; 95%CI: 082-0.99) with each increase 
of 1 kg body weight. Many children with 
HIV-1 infection have chronic problems with 
linear growth and weight gain which might 
lead in this case to malnutrition and a worth 
outcome in the LTFU/mortality group.9,10,11 
Even though WHO staging was not 
significant in the multivariate analysis, 
weight and staging considered an important 
role on a pathological basis. According to 
WHO staging, children under 15 years with 
unexplained moderate malnutrition who are 
adequately responding to standard therapy 
as stage III.7  
In low income countries, it is 
estimated that 50% of HIV-infected infants 
will die before the age of two.12 The overall 
median age during the first visit was 2.6 
years old and the median age at ARV 
initiation was 3.21 years indicating a fast and 
(Month) 
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swift diagnostic assessment, compared to 
the Asian average of 7.0 years8 and South 
African median age of 49 months old (4.08 
years).5  Overall ARV indication is around 6.5 
months after the first visit. This gap can be 
explained through the overall poor condition 
in which the children arrive at the hospital. 
This gap is smaller among 5.24 months 
children that continue therapy compared to 
7.35 months children that are LTFU. The age 
at first visit and among those who begin ARV 
was much younger in the group that are 
LTFU/mortality compared to that of those 
who will continue therapy. The hazard ratio 
results in a 17% increase in possibility that 
with each year of age the child is more likely 
to continue therapy, so that the older the 
child the better the adherence (Table 1). 
This again may be related to the overall poor 
physical health of the children when 
presenting at the hospital. As above, the 
WHO staging was worth in the 
LTFU/mortality group. Though if younger 
children already present in a poorly 
condition, it would be misleading to directly 
compare them purely based on age.  
Moreover drug dosing in younger children is 
complicated, as dosage increases with 
weight. Patients must be consistently 
monitored, in order to ensure that they are 
receiving adequate doses of each drug to 
achieve therapeutic levels and fully suppress 
the virus, while also avoiding toxicities 
related to excess dosing.13 Many 
medications are also not formulated for easy 
administration to infants and very young 
children. Such children require either 
dispersible tablets or syrup formulations, 
which are often more expensive than 
tablets. In the case of syrup these may be 
less palatable, compromising adherence and 
efficacy.14  
Bali is divided into nine districts. 
Sanglah General Hospital lies in the 
metropolitan district of Denpasar. Denpasar 
is also the capital city of the Province of Bali. 
Therefore it is not surprising that 25.36% of 
all HIV cases are living in Denpasar. 
Nevertheless no significance was found if 
the child comes from Denpasar or outside of 
Denpasar, resulting in difficulty for the 
caregiver to attend the monthly check up. 
Sanglah General Hospital is the largest 
centre in Bali that provide ARV therapy to 
children. Some caregivers have to take a day 
of and drive several hours to the hospital.  
Most children had the support of either both 
biological parents, or one parent (69.57%), 
only 10.87% of the children were raised by 
extended family members (Table 1). 
However, those who raised the child, did not 
show a significant to LTFU/death, compared 
to continuing therapy.  
Limitation of this study is small 
sample size. In total only 138 eligible 
samples were analysed out of 211 cases. 
Another limitation was uncertainty about 
whether or not the child in question was 
actually LFTU or had died and therefore was 
LTFU. Additionally, double entry/reporting 
of patients might occur, noting that specific 
identification is needed to sign up to receive 
ARV treatment in Indonesia.  
 
Conclusion 
The incidence of LTFU/mortality was 3.28 
per 100 child-month, where 95 (69.84%) 
children continued therapy for more than 12 
month. The predictor for LTFU/mortality in 
this study was weight at first visit with a 
protective factor of 10% with each increased 
kilogram. The higher the WHO stage when 
starting ARV therapy, the higher the risk for 
LTFU/mortality in this study.  
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Table 1: Significance of children’s characteristics towards LTFU/mortality 
Characteristics LTFU n (%) Not LTFU n (%) Hazard ratio 95%CI p value 
Gender 
Boy 
Girl 
 
21 (27.27) 
22 (36.07) 
 
56 (72.73) 
39 (63.93) 
 
Ref 
0.72 
 
 
0.40-1.31 
 
 
0.284 
Address 
Denpasar 
Outside of Denpasar 
Missing 
 
12 (33.33) 
30 (31.85) 
1 (14.29) 
 
24 (66.67) 
65 (68.42) 
6 (85.71) 
 
Ref 
0.89 
0.35 
 
 
0.46-1.75 
0.05-2.68 
 
 
0.60 
Age at first visit (years) 
Median (IQR) 
 
1.42 (0.93-3.24) 
 
2.99 (1.59-4.63) 
 
0.83 
 
0.70-0.98 
 
0.024 
Age at ARV initiation (years) 
Median (IQR) 
 
2.03 (0.52-3.73) 
 
3.64 (1.12-4.91) 
 
0.84 
 
0.72-0.99 
 
0.035 
ARV starting year 
2010 
2011 
2012 
2013 
2014 
2015 
 
4 (20.00) 
2 (16.67) 
10 (41.67) 
12 (35.29) 
10 (40.00) 
5 (21.71) 
 
16 (80.00) 
10 (83.33) 
14 (58.33) 
22 (64.71) 
15 (78.26) 
18 (78.26 
 
Ref 
0.83 
2.46 
2.04 
2.46 
1.67 
 
 
0.15-4.54 
0.78-7.75 
0.66-6.34 
0.77-7.85 
0.44-6.26 
 
 
0.48 
Primary care giver 
Both parents 
Mother/father 
Extended family 
NGO 
Missing 
 
9 (47.37) 
20 (25.97) 
5 (33.33) 
1 (16.67) 
8 (38.10) 
 
10 (52.63) 
57 (74.03) 
10 (66.67) 
5 (83.33) 
13 (61.90) 
 
Ref 
0.48 
0.66 
0.36 
0.75 
 
 
0.22-1.07 
0.22-1.97 
0.05-2.83 
0.29-1.96 
 
 
0.430 
WHO stage at first visit 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Missing 
 
5 (20.83) 
7 (25.00) 
13 (26.00) 
16 (55.17) 
2 (28.57) 
 
19 (79.17) 
21 (75.00) 
37 (74.00) 
13 (26.00) 
5 (71.43) 
 
Ref 
1.17 
1.26 
3.21 
1.47 
 
 
0.37-3.69 
0.45-3.54 
1.18-8.77 
0.29-7.58 
 
 
0.168 
WHO stage starting ART 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Missing 
 
2 (10.53) 
5 (22.73) 
16 (27.59) 
17 (51.52) 
5 (50.00) 
 
17 (89.47) 
17 (77.27) 
42 (72.41) 
16 (48.48) 
3 (50.00) 
 
Ref 
2.29 
2.97 
6.63 
5.58 
 
 
0.45-11.82 
0.68-12.93 
1.53-28.72 
0.93-33.42 
 
 
0.01 
Weight at first visit (kg) 
Median (IQR) 
 
7.5 (3.7) 
 
10 (4.2) 
 
0.88 
 
0.80-0.97 
 
0.007 
Hemoglobin (gr/dl) 
Median (IQR) 
 
10.1 (2.1) 
 
10.6 (2.3) 
 
0.99 
 
0.99-1.00 
 
0.406 
CD4% 
Median (IQR) 
 
9 (18) 
 
10 (13.6) 
 
1.00 
 
1.00-1.01 
 
0.050 
CD4 cell count 
Median (IQR) 
 
289.5 (462) 
 
264 (419) 
 
1.00 
 
0.99-1.00 
 
0.629 
Malnutrition 
Yes 
No 
 
22 (47.83) 
21 (22.83) 
 
24 (52.17) 
71 (77.17) 
 
Ref 
2.57 
 
 
1.41-4.67 
 
 
0.002 
Tuberculosis 
Yes 
No 
 
6 (18.18) 
37 (35.24) 
 
27 (81.82) 
68 (64.76) 
 
Ref 
0.46 
 
 
0.19-1.07 
 
 
0.074 
Anaemia 
Yes 
No 
 
14 (66.67) 
29 (24.79) 
 
7 (33.33) 
88 (75.21) 
 
Ref 
4.62 
 
 
2.42-8.82 
 
 
0.001 
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Table 2. Multivariate analyses of predictors for LTFU/mortality in children receiving ARV therapy 
Variables Adjusted hazard ratio 95%CI p value 
Lower Upper 
CD4% 
WHO staging starting ARV 
Weight at first visit 
1.000 
1.158 
0.903 
0.99 
0.99 
0.82 
1.00 
1.35 
0.99 
0.060 
0.065 
0.036 
     
This study found no significance 
predictors of socio demographic 
characteristics and clinical conditions such as 
haemoglobin level or CD4 cell count. 
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